The Purple Sky Store
Women’s Relaxed V-Neck Tee (Embroidered Purple Ribbon)
Women’s Relaxed V-Neck Tee (Embroidered Purple Ribbon)
Couldn't load pickup availability
Garment Name: Empower V-Neck Support Tee
Enjoy effortless style with a purpose in the Empower V-Neck Support Tee, designed for comfort and versatility. With its relaxed fit and soft fabric, this women’s V-neck t-shirt is perfect for polished everyday wear. The flattering V-neckline adds a stylish touch, making it easy to dress up or keep casual. Crafted from a blend of 52% airlume combed and ring-spun cotton and 48% polyester in heather colors, this tee offers all-day softness and durability.
More than just a wardrobe staple, this tee contributes to a meaningful cause. 40% of all revenue from the Empower V-Neck Support Tee goes to Sky Foundation, a non-profit that funds pancreatic cancer research, so every purchase helps to make a positive impact.
- Soft and lightweight fabric (4.2 oz./yd.² or 142.4 g/m²) for all-day comfort
- Relaxed fit with a side-seamed construction for a flattering silhouette
- Stylish V-neckline
- Heather colors: 52% airlume combed and ring-spun cotton, 48% polyester
- Yarn diameter: 32 singles for a smooth finish
Note: Wear this tee with pride, knowing you’re supporting pancreatic cancer research and making a difference.
Share
















Recent News
View all-
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
-
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
-
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...